94 related articles for article (PubMed ID: 10561278)
1. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies.
DiPaola RS; Rafi MM; Vyas V; Toppmeyer D; Rubin E; Patel J; Goodin S; Medina M; Medina P; Zamek R; Zhang C; White E; Gupta E; Hait WN
J Clin Oncol; 1999 Jul; 17(7):2213-8. PubMed ID: 10561278
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies.
Thalasila A; Poplin E; Shih J; Dvorzhinski D; Capanna T; Doyle-Lindrud S; Beers S; Goodin S; Rubin E; DiPaola RS
Cancer Chemother Pharmacol; 2003 Aug; 52(2):119-24. PubMed ID: 12768320
[TBL] [Abstract][Full Text] [Related]
3. Overcoming bcl-2- and p53-mediated resistance in prostate cancer.
DiPaola RS; Aisner J
Semin Oncol; 1999 Feb; 26(1 Suppl 2):112-6. PubMed ID: 10190792
[TBL] [Abstract][Full Text] [Related]
4. Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).
Pillai RN; Aisner J; Dahlberg SE; Rogers JS; DiPaola RS; Aisner S; Ramalingam SS; Schiller JH
Cancer Chemother Pharmacol; 2014 Jul; 74(1):177-83. PubMed ID: 24858462
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
DiPaola RS; Chen YH; Stein M; Vaughn D; Patrick-Miller L; Carducci M; Roth B; White E; Wilding G
J Transl Med; 2010 Feb; 8():20. PubMed ID: 20178647
[TBL] [Abstract][Full Text] [Related]
6. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.
Motzer RJ; Schwartz L; Law TM; Murphy BA; Hoffman AD; Albino AP; Vlamis V; Nanus DM
J Clin Oncol; 1995 Aug; 13(8):1950-7. PubMed ID: 7636535
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
[TBL] [Abstract][Full Text] [Related]
8. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V; Myers J; Morrison W; Gillenwater A; Ang KK; Lippman SM; Goepfert H; Hong WK
J Clin Oncol; 2001 Jun; 19(12):3010-7. PubMed ID: 11408495
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
Vaishampayan U; Flaherty L; Du W; Hussain M
Cancer; 2001 Aug; 92(3):519-23. PubMed ID: 11505395
[TBL] [Abstract][Full Text] [Related]
11. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.
Pili R; Kruszewski MP; Hager BW; Lantz J; Carducci MA
Cancer Res; 2001 Feb; 61(4):1477-85. PubMed ID: 11245454
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice.
Conley BA; Ramsland TS; Sentz DL; Wu S; Rosen DM; Wollman M; Eiseman JL
Cancer Chemother Pharmacol; 1999; 43(3):183-97. PubMed ID: 9923548
[TBL] [Abstract][Full Text] [Related]
13. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.
Shin DM; Glisson BS; Khuri FR; Clifford JL; Clayman G; Benner SE; Forastiere AA; Ginsberg L; Liu D; Lee JJ; Myers J; Goepfert H; Lotan R; Hong WK; Lippman SM
J Clin Oncol; 2002 Jan; 20(2):364-70. PubMed ID: 11786562
[TBL] [Abstract][Full Text] [Related]
14. Enhanced apoptosis and radiosensitization by combined 13-cis-retinoic acid and interferon-alpha2a; role of RAR-beta gene.
Ryu S; Stein JP; Chung CT; Lee YJ; Kim JH
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):785-90. PubMed ID: 11697325
[TBL] [Abstract][Full Text] [Related]
15. Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.
Zhang LY; Huang JS; Pi ZM; Yu MY
Int J Clin Exp Pathol; 2015; 8(9):11340-7. PubMed ID: 26617858
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA
Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508
[TBL] [Abstract][Full Text] [Related]
17. Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.
Sonawane P; Cho HE; Tagde A; Verlekar D; Yu AL; Reynolds CP; Kang MH
Br J Pharmacol; 2014 Dec; 171(23):5330-44. PubMed ID: 25039756
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-tumor effect of 13-cRA and IFN-alpha/beta in mouse renal cell carcinoma.
Taguchi I; Hara I; Gohji K; Arakawa S; Kamidono S
Int J Oncol; 1998 Jul; 13(1):145-9. PubMed ID: 9625816
[TBL] [Abstract][Full Text] [Related]
19. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Wadler S; Damle S; Haynes H; Kaleya R; Schechner R; Berkenblit R; Ladner RD; Murgo A
J Clin Oncol; 1999 Jun; 17(6):1771-8. PubMed ID: 10561214
[TBL] [Abstract][Full Text] [Related]
20. [Study on the biological activity and molecular mechanism of IFNalpha on human myeloma cell line Sko-007].
Song L; Li Y; Sun Y; Shen B
Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):517-9. PubMed ID: 12482347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
